© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
June 24, 2022
Expert perspectives on the role of transarterial radioembolization in unresectable hepatocellular carcinoma following FDA approval.
Sharing the first patient case of unresectable hepatocellular carcinoma, experts consider optimal screening and diagnosis practices in this setting.
June 21, 2022
During a Targeted Oncology case-based roundtable event, Richard S. Finn, MD, discussed the case of a patient with hepatocellular cancer with a medical history of Crohn disease, cirrhosis, and variceal bleeding.
June 09, 2022
Amaia Lujambio Goizueta, PhD, discusses the unanswered questions currently circulating the hepatocellular carcinoma field.
May 17, 2022
Amaia Lujambio Goizueta, PhD, discusses a new approach to overcoming resistance to immunotherapy for patients with hepatocellular carcinoma.
May 08, 2022
The phase 2 clinical trial of the combination therapy, GT90001 and nivolumab, for the treatment of patients with advanced hepatocellular carcinoma has dosed its first patient.
May 03, 2022
Nino Balanchivadze, MD, FACP, discusses the rationale for evaluating toxicity based on race in the KEYNOTE-189 study.
May 02, 2022
Surface Oncology announced the initiation of new trials of the investigational agent SRF388 in patients with hepatocellular carcinoma and non–small cell lung cancer.
April 25, 2022
Priority review for a biologics license application has been granted by the FDA for tremelimumab as treatment of patients with unresectable hepatocellular carcinoma.
The FDA has granted orphan drug designation to the STA3 inhibitor, TTI-101, for the treatment of hepatocellular carcinoma. The agent is currently being investigated in a phase 1 clinical trial.